A low-cost option for a high-risk period
Controlling blood pressure is central to care after a stroke, when survivors face a meaningful risk of another event. New preliminary research presented at an American Heart Association meeting suggests that spironolactone, an inexpensive diuretic, could help more patients reach recommended blood-pressure levels when it is added to usual post-stroke care.
In the study, patients receiving spironolactone had lower systolic blood pressure after three months than people receiving standard care alone. The results are notable because spironolactone is an established medicine that can cost as little as about $6 a month, according to the report. The findings do not by themselves establish a new standard of care, but they point to a potentially accessible tool for a difficult clinical problem.
What the study found
Researchers at five U.S. hospitals enrolled 160 adults who had survived a stroke. Participants had an average age of 63. About half had experienced a hemorrhagic stroke, caused by bleeding in or around the brain, while the remainder had had an ischemic stroke caused by a clot.
The team randomly assigned half of the participants to receive spironolactone in addition to their normal post-stroke care. The other half continued with usual care. After three months, the group taking spironolactone had an average systolic blood pressure of 126 mm Hg, compared with 133 mm Hg in the standard-care group.
That seven-to-eight-point difference matters because systolic pressure is the upper number in a blood-pressure measurement: it reflects the pressure in blood vessels as the heart beats. The study also found a difference in the proportion of participants who reached the recommended goal of less than 130/80. About 52% of those taking spironolactone met that goal at three months, compared with 30% of those receiving standard care.
Dr. Jordana Cohen, an associate professor of medicine and epidemiology at the University of Pennsylvania and a co-lead researcher, said the team had expected a benefit but was surprised by the scale of the blood-pressure reduction described in the report.
Why spironolactone could help
Spironolactone works by blocking aldosterone, a hormone that tells the kidneys to retain salt and water. Blocking that signal increases urination and reduces fluid in the body, which can lower blood pressure. Medicines with this effect are often called diuretics or “water pills.”
That mechanism is well understood, but the study focuses on its use during recovery from stroke, when consistently reaching a pressure target can be challenging. The researchers emphasized that lowering blood pressure is an important part of preventing another stroke. Their background material noted that nearly one in four stroke survivors will have another stroke and that a large share of strokes can be prevented.
The apparent affordability of the drug is also significant. Managing stroke risk can require ongoing treatment and repeated monitoring, and lower-cost options may be easier for health systems and patients to sustain. Still, price alone is not enough to determine the right treatment: clinicians need to consider a patient’s existing medicines, kidney function, potassium levels and other individual factors.
Promising results, but still preliminary
The research was reported at a scientific meeting rather than described in the supplied text as a completed peer-reviewed journal publication. That distinction matters. Conference findings can change as researchers complete analyses, submit their work for review and compare their results with larger trials.
The study was also relatively small, with 160 participants, and the supplied report describes outcomes over the first three months. It provides a useful signal that spironolactone may improve blood-pressure control after either major type of stroke, but it does not establish from this study alone that the medicine directly prevents recurrent strokes.
Those limits do not diminish the practical question raised by the work: whether a familiar, cheap drug can help close a persistent treatment gap for survivors who remain above recommended blood-pressure levels despite usual follow-up. Larger studies would be needed to assess long-term outcomes, safety across broader patient populations and whether the pressure reductions translate into fewer recurrent strokes.
What patients should take from it
For now, the study is not a reason for stroke survivors to begin, stop or change medication on their own. Instead, it gives patients and clinicians another research-backed topic to discuss during follow-up visits, particularly when blood pressure remains above target.
The clearest takeaway is the importance of continued blood-pressure management after a stroke. The trial suggests spironolactone may be one affordable addition to that effort for some people. Whether it becomes widely used for this purpose will depend on further research and on decisions made with a treating clinician who can weigh the benefits and risks for an individual patient.
This article is based on reporting by Medical Xpress. Read the original article.
Originally published on medicalxpress.com
